Table of Contents
<< Previous Issue | Nov 2011 (Vol: 2011, Issue: 11) | Next Issue >> |
- Section: Cartoons
-
Birthday
- Section: Licensing
-
Biogen Idec and Portola Pharmaceuticals Collaborate on Oral Syk Inhibitors for Autoimmune Diseases
-
Aslan Pharmaceuticals Licenses Regional Rights to BMS’ Early-Stage Cancer Drug
-
Lundbeck and Otsuka Forge US$1.8 B Global CNS Alliance
- Section: Mergers & Acquisitions
-
Roche Expands its HCV Pipeline with Anadys Pharmaceuticals Acquisition
-
Cubist Looks to Opioid Receptor Antagonists with Potential US$415 M Adolor Takeover
-
ViroPharma to Broaden its Orphan Drug Portfolio with DuoCort Pharma Acquisition
-
Repligen Agrees to Buy Novozymes Biopharma Sweden to Increase its Revenue Potential
-
Salix Expands its Product Portfolio with US$300 M Oceana Therapeutics Buyout
- Section: Research & Development
-
miRagen Receives Validation of its miRNA Platform with Servier Collaboration
-
MedImmune to Advance AgonOx’s OX40 Cancer Agonists in Global Collaboration
-
Celgene Invests US$45 M in Quanticel in Cancer Collaboration with Buyout Option
-
Ablynx and Merck Serono Form Third Nanobody® Collaboration